These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22327971)

  • 1. Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?
    Tang P; Kwok PC; Tong Z; Yang R; Raper JA; Chan HK
    Pharm Res; 2012 Jul; 29(7):1797-807. PubMed ID: 22327971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
    Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
    AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations.
    Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R
    Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
    Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
    Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface.
    Farkas D; Bonasera S; Bass K; Hindle M; Longest PW
    Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFD-DEM investigation of the effects of aperture size for a capsule-based dry powder inhaler.
    Zhu Q; Kakhi M; Jayasundara C; Walenga R; Behara SRB; Chan HK; Yang R
    Int J Pharm; 2023 Nov; 647():123556. PubMed ID: 37890648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Exploration of Factors Affecting
    Ruzycki CA; Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
    [No Abstract]   [Full Text] [Related]  

  • 12. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems.
    Wong W; Fletcher DF; Traini D; Chan HK; Crapper J; Young PM
    J Pharm Sci; 2011 Jul; 100(7):2744-54. PubMed ID: 21360707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H; Safioti G; Keegstra JR; Gopalan G
    Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
    Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
    Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of USP Induction Ports, Glass Sampling Apparatus, and Inhaler Device Resistance on Aerodynamic Patterns of Fluticasone Propionate-Loaded Engineered Mannitol Microparticles.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    AAPS PharmSciTech; 2019 May; 20(5):197. PubMed ID: 31123855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).
    Zhou QT; Tong Z; Tang P; Citterio M; Yang R; Chan HK
    AAPS J; 2013 Apr; 15(2):511-22. PubMed ID: 23371759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. InVitro Evaluation of Optimal Inhalation Flow Patterns for Commercial Dry Powder Inhalers and Pressurized Metered Dose Inhalers With Human Inhalation Flow Pattern Simulator.
    Hira D; Okuda T; Mizutani A; Tomida N; Okamoto H
    J Pharm Sci; 2018 Jun; 107(6):1731-1735. PubMed ID: 29428382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCF-engineered powders for delivery of budesonide from passive DPI devices.
    Lobo JM; Schiavone H; Palakodaty S; York P; Clark A; Tzannis ST
    J Pharm Sci; 2005 Oct; 94(10):2276-88. PubMed ID: 16136557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.